NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Corbus Pharmaceuticals Holdings, Inc. CRBP
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-5.90
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-54.2%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 13-year series below
Revenue
Net income
Per share
USD -5.90
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-54.2%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-48.5%
Each USD of equity lost 54 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years+149.3%
Change, 10 years—
The share count grew 149% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 168.2M
total assets, end of FY2025
Total assetsUSD 168.2M
EquityUSD 147.5M
CashUSD 28.5M
Current ratio8.07×
Equity funds 88% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.1
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
·
·
−0.0
−0.0
−0.0
·
Income tax $B
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.1
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−5.90
−3.68
−10.31
−10.15
−11.15
−1.42
−1.12
−0.98
−0.65
−0.49
−0.28
−0.13
−0.09
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−54.2
−59.3
−342.0
−83.0
−79.8
−432.7
−424.3
−130.5
−97.2
−223.4
−119.2
−124.5
·
Shares out B
0.02
0.01
0.00
0.00
0.00
0.10
0.06
0.06
0.06
0.04
0.04
0.03
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
39 of 39
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed